Direct laryngoscope and videolaryngoscope are the dominant endotracheal intubation tools. Styletubation technique (using a video-assisted intubating stylet) has shown its advantages regarding in short intubation time, high success rate, less stimulation, and operator’s satisfaction. The learning curve can be steep but easy to overcome if the technical pitfalls could be avoided. Conditions make styletubation challenging include secretions/blood, short/stiff neck, restricted mouth opening and cervical spine mobility, anatomical abnormalities over head and neck regions, and obesity, etc. In this clinical report, we present the effectiveness and efficiency of routine use of the styletubation for tracheal intubation in a super-super obese patient (BMI 103 kg/m2) undergoing bariatric surgery with laparoscopic sleeve gastrectomy.

A finite element model of 100m X-BOW polar exploration cruise is established. The entire ship frequency response analysis was carried out, comparing the simulated values with the test values, the maximum error is 22%, but only 0.24mm/s difference, the error can be ignored from the perspective of comfort, therefore, the simulation results meet the requirements of engineering accuracy and verify the effectiveness of the model. According to the solution method for global modal equivalent mass, combing the spatial distribution principle of local modal mass, the method for solving the equivalent mass of a single local mode in mixed mode is proposed, the equivalent mass of the local vibration region of 100m X-BOW polar exploration cruise ship is solved by this method, tuned mass dampers mass ratio parameters are calculated using the equivalent mass. According to the analysis, tuned mass dampers has 31dB vibration absorption effect at 13.4Hz when the mass ratio is 0.05, it also has certain control effect at 10Hz and 18.8Hz, the control effect is 3dB and 2dB respectively, the overall control frequency band is flat and robust.

The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become a dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its effectiveness against Omicron EG.5, comparing it with its progenitor vaccine, SCTV01E (NCT05933512). As of September 12, 2023, 429 participants aged ≥18 years were randomized to SCTV01E (N=215) or SCTV01E-2 (N=214) groups. Both vaccines showed increases in neutralizing antibody (nAb) against Omicron EG.5, with a 5.7-fold increase and a 9.0-fold increase in SCTV01E and SCTV01E-2 groups 14 days post-vaccination, respectively. The predetermined statistical endpoints were achieved, showing that the geometric mean titer (GMT) of nAb and the seroresponse rate (SRR) against Omicron EG.5 were significantly higher in the SCTV01E-2 group compared to SCTV01E. Additionally, SCTV01E and SCTV01E-2 induced a 5.5-fold and a 5.9-fold increase of nAb against XBB.1, respectively. Reactogenicity was generally mild and transient. No vaccine related SAEs, AESIs or deaths were reported. In summary, SCTV01E-2 elicited robust neutralizing responses against Omicron EG.5 and XBB.1 without safety concerns, underlining its potential as a versatile COVID-19 vaccine against SARS-CoV-2 variants.